Matisse Capital Kala Pharmaceuticals, Inc. Transaction History

Matisse Capital

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 12, 2022	SELL	$0.61 - $1.84 $2,806 - $8,464	-4,600 Reduced 11.11%	36,800 $51,000
Q4 2021 Feb 04, 2022	SELL	$1.16 - $2.74 $17,052 - $40,278	-14,700 Reduced 26.2%	41,400 $50,000
Q1 2021 May 14, 2021	BUY	$6.24 - $9.58 $1,872 - $2,874	300 Added 0.54%	56,100 $378,000
Q4 2020 Feb 12, 2021	BUY	$6.28 - $8.79 $34,540 - $48,344	5,500 Added 10.93%	55,800 $378,000
Q2 2020 Jul 28, 2020	SELL	$8.33 - $13.79 $256,564 - $424,732	-30,800 Reduced 37.98%	50,300 $529,000
Q1 2020 May 07, 2020	BUY	$3.83 - $8.79 $101,878 - $233,813	26,600 Added 48.81%	81,100 $713,000
Q4 2019 Feb 12, 2020	BUY	$3.36 - $4.81 $26,880 - $38,480	8,000 Added 17.2%	54,500 $201,000
Q3 2019 Oct 28, 2019	BUY	$3.57 - $6.58 $7,140 - $13,160	2,000 Added 4.49%	46,500 $177,000
Q2 2019 Aug 13, 2019	BUY	$4.93 - $8.8 $3,944 - $7,040	800 Added 1.83%	44,500 $284,000
Q1 2019 Apr 24, 2019	BUY	$5.19 - $8.97 $226,803 - $391,989	43,700 New	43,700 $361,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $8.67M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

Stay updated on Matisse Capital with notifications on news.